Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Hepatitis C prevention, control efforts should focus on incarcerated individuals

More than one in nine people with hepatitis C in Canada spend time in a correctional facility each year and researchers said this presents a unique opportunity to focus hepatitis C prevention and control efforts in incarcerated populations.

Published
17 December 2015
From
EurekAlert (press release)
Curing Hepatitis C, in an Experiment the Size of Egypt

A new approach tested in Egypt could become the blueprint for providing cutting-edge medicines to the poor.

Published
16 December 2015
From
New York Times
Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure

Month-by-month tracking of the prices paid in India for the chemicals used to make hepatitis C direct-acting antivirals shows that it is now possible to make and

Published
14 December 2015
By
Keith Alcorn
Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection

Merck's grazoprevir/elbasvir combination cured 93% of people with HIV and hepatitis C co-infection, was well-tolerated and did not appear to interact with antiretrovirals, according to final results from

Published
11 December 2015
By
Liz Highleyman
Study Probes Value of Hepatitis C Treatment at All Stages of Liver Fibrosis

Treating hepatitis C sooner rather than later -- even at the early stages of liver fibrosis -- is worth the thousands of dollars it costs to pay for the new, more effective drugs, according to researchers who developed a model to assess historical treatment data.

Published
10 December 2015
From
MD Magazine
Survey shows hepatitis infection rates falling: Health Minister

The previous survey, conducted in 2008, set the overall infection rate at 10%, compared to the 7% reported by the survey announced on Monday. This puts the total number of hepatitis-C cases at approximately 3.5 million, and the number of hepatitis-B cases at 800,000, according to the survey results.

Published
09 December 2015
From
Daily News Egypt
European Physicians Report Strong but Variable Uptake of All-Oral Interferon-Free Hepatitis C Virus Regimens Across EU5 Countries

Differences between EU5 markets were most apparent in the treatment of non-cirrhotic patients with lower liver fibrosis scores, who are typically deprioritized for access to IFN-free therapies. This effect is exemplified in the United Kingdom, where 45 percent of non-cirrhotic treatment-naive genotype-1 patients were being treated with IFN dual therapy or first generation protease inhibitor triple therapy, according to survey results, though this will change rapidly with the recent approval of new direct acting antivirals in the UK in late 2015.

Published
09 December 2015
From
Decision Resources press release
United States faces biggest burden of hepatitis C treatment costs before 2020

The cost of treating hepatitis C (HCV) is likely to decline dramatically over the next decade in the United States, not because of cuts in drug prices

Published
09 December 2015
By
Keith Alcorn
A New Look Behind the Pricing of a $1,000 Pill

Last week, the U.S. Senate Finance Committee concluded an 18-month investigation into Gilead Science's pricing of new hepatitis C drugs. It found that Gilead “pursued a calculated scheme for pricing and marketing its hepatitis C drugs based on one goal: maximizing revenue, regardless of the human consequences.”

Published
08 December 2015
From
Open Society Foundations
The Impact Of New Hepatitis C Drugs On National Health Spending

While spending on hepatitis C drugs in 2015 remains very high ($14.4 billion is a reasonable estimate, assuming $3.5 billion in Q4), it represents a much smaller increase ($1.9 billion) than experienced in 2014 ($12.3 billion). This means that in 2015, hepatitis C drugs will have added less than 0.1 percentage points to the growth rate in national health expenditures and 0.6 percentage points to the growth rate in prescription drug spending.

Published
08 December 2015
From
Health Affairs (blog)

Filter by country